| 主权项 |
1. A method of treating a cancer selected from the group consisting of non-small cell lung cancer and breast cancer with an mTOR inhibitor and an αvβ3 integrin antagonist, wherein the mTOR inhibitor is selected from the group consisting of ridaforolimus, everolimus, temsirolimus and combinations thereof, and the αvβ3 integrin antagonist is a compound of structural formula I: wherein each R1 is independently selected from the group consisting of hydrogen, C1-4 alkyl and cyclopropyl; or two R1 substituents, when on the same carbon atom, are taken together with the carbon atom to which they are attached to form a spirocyclopropyl group; R2 is hydrogen or C1-4 alkyl; R3 is mono- or di-substituted quinolinyl, pyridinyl or pyrimidinyl; wherein the substituents are each independently selected from the group consisting of hydrogen, halo, phenyl, C1-4 alkyl, C3-6 cycloalkyl, C1-3 alkoxy, amino, C1-3 alkylamino, alkylamino), hydroxyl, cyano, trifluoromethyl, trifluoroethyl, trifluoromethoxy and trifluoroethoxy. |
